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Abstract
AIM
To evaluate selected intestinal parameters of oxidative 
stress, and antioxidant capacity in adult celiac disease 
patients with extraintestinal manifestations.
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METHODS
The study involved 85 adult patients divided into the 
following subgroups: (1) patients with newly diagnosed 
celiac disease (CD) (n  = 7); (2) celiac patients not 
adhering to a gluten-free diet (GFD) (n  = 22); (3) 
patients with CD on the GFD (n  = 31); and (4) patients 
with functional disorders of the gastrointestinal 
tract, serving as controls (n  = 25). Celiac patients 
presented with non-classic symptoms or extraintestinal 
manifestations. Standard blood tests including serum 
antioxidant levels (uric acid, bilirubin, and vitamin D), 
celiac antibody levels, and histopathological status of 
duodenal biopsy specimens have been determined. 
The expression of mRNA for tumor necrosis factor α 
(TNF-α), interleukin 1β (IL-1β), interleukin 10 (IL-10), 
superoxide dismutase (SOD), heat-shock protein 70 
(HSP-70), hypoxia-inducible factor 1 (HIF-1α), and BAX 
in the duodenal mucosa of patients was analyzed by 
reverse transcriptase-polymerase chain reaction. 
RESULTS
The mean plasma uric acid level in patients with active 
CD (newly diagnosed and nonadherent patients) and 
treated celiac patients was significantly higher than 
in controls (260.17 ± 53.65 vs  190.8 ± 22.98, P  < 
0.001, and 261.7 ± 51.79 vs  190.8 ± 22.98, P  < 0.001, 
respectively). The mean bilirubin concentration in active 
and treated celiac patients was significantly lower than 
in controls (8.23 ± 5.04 vs  10.48 ± 4.08, P  < 0.05 and 
8.06 ± 3.31 vs  10.48 ± 4.08, P  < 0.05, respectively). 
The mean plasma vitamin D level was significantly 
lower in active celiac patients than in treated celiac 
patients and controls (19.37 ± 9.03 vs  25.15 ± 11.2, P  
< 0.05 and 19.37 ± 9.03 vs  29.67 ± 5.12, P  < 0.001, 
respectively). The expression of TNF-α, IL-10, and 
HSP-70 mRNAs was significantly elevated in the celiac 
groups regardless of the diet when compared with 
controls. Patients on the GFD presented a significantly 
lower mRNA expression of TNF-α and IL-10 than 
in newly diagnosed and nonadherent patients (P  < 
0.05). The expression of SOD mRNA was significantly 
elevated in celiac patients compared with controls (P  
< 0.05), with a significant difference between treated 
and untreated patients (P  < 0.05). The expression of 
HIF-1α mRNA and BAX mRNA was significantly higher 
in patients with active CD compared with controls and 
patients on GFD, while no difference was observed 
between the latter two groups. 
CONCLUSION
Increased intestinal expression of HSP-70 despite GFD 
indicates that GFD only partially reduced oxidative 
stress. CD patients exhibited an oxidative imbalance 
and inflammatory response despite GFD. Uric acid may 
act as an important antioxidant in CD.
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Core tip: Oxidative stress has been implicated in 
gliadin toxicity. Additional measures aimed at reducing 
oxidative imbalance may prove to be effective 
supplementary therapy. We demonstrated increased 
duodenal expression of hypoxia-inducible factor 1 (HIF-
1α), heat-shock protein 70 (HSP-70), and superoxide 
dismutase in adult celiac patients with extraintestinal 
manifestations as a defensive reaction to oxidative 
stress. Hence, HSP-70 and HIF-1α might be potential 
novel biomarkers of celiac disease (CD). Increased 
HSP-70 expression, both in treated and untreated 
celiac patients, suggests that oxidative stress as well as 
histopathological alterations in duodenal mucosa persist 
despite gluten-free diet. Our data confirm the increased 
serum levels of uric acid in patients with CD compared 
with controls as a result of oxidative stress. 
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INTRODUCTION 
Celiac disease (CD) is an inflammatory disorder of 
the small intestine, which is caused by the gluten 
fraction of wheat or the homologous proteins from 
barley and rye in genetically predisposed individuals[1]. 
Histologically, these lesions include intraepithelial 
lymphocytosis, crypt hypertrophy, and villous at­
rophy, resulting in an inadequate absorption of mi­
cronutrients and macronutrients from the intestinal 
tract. The clinical presentation of CD is heterogeneous 
and varies with the age of patients, duration and 
intensity of the disease, and possible presence of 
extraintestinal disorders[1]. In adults, a variety of 
clinical manifestations have been described, including 
the non­classic or asymptomatic form of CD. 
The pathogenesis of CD is complex and not fully 
understood. Besides genetic predisposition, the 
immunologic mechanism has been proposed because 
both the innate and adaptive immune responses 
contribute to the mucosal inflammation in patients 
with CD[2]. The disruption of the intestinal epithelial 
barrier makes it more permeable to gluten peptides, 
thus exacerbating the inflammatory process if gluten 
peptides are present in the intestinal lumen.
Recent studies have indicated a direct cytotoxic 
effect of gluten on enterocytes[3]. Moreover, it has 
been proposed that oxidative stress is one of the 
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mechanisms responsible for gliadin toxicity[4]. 
Recent data have also suggested the importance of 
hypoxia­inducible factor 1 (HIF­1) in maintaining the 
functions of the intestinal epithelial barrier[5]. Although 
activation of HIF­1 is mainly regulated by hypoxia[6], 
it is now established that HIF­1 signaling can also 
be triggered under inflammatory conditions[7­10]. 
Vannay et al[11] have shown the increased mucosal 
expression of HIF­1α in children with untreated CD, 
suggesting the involvement of this signaling factor in 
the pathomechanism of the disease. The regulation of 
HIF­1 is a complex process. Among these regulatory 
mechanisms, a direct effect of reactive oxygen species 
(ROS) on the HIF­1α subunit has received a great 
deal of attention, but there are contradictory literature 
data with respect to association between HIF­1α 
and ROS[12]. Some studies have indicated that heat 
shock proteins and the family of chaperones could 
play important roles in the pathology of CD[13­15]. The 
expression of HSPs can be markedly upregulated 
in epithelial cells under extreme conditions by the 
mechanism involving the expression and release of 
proinflammatory mediators, such as tumor necrosis 
factor alpha (TNF­α) or an activation of oxidative 
stress[16]. All these factors can trigger apoptosis[17,18], 
but the decision for a cell to undergo apoptosis 
depends on the balance between proapoptotic and 
antiapoptotic signals. For instance, HSPs may exert 
antiapoptotic effects and contribute to preservation 
of intestinal epithelial barrier integrity[19]. This process 
can be executed either by the extrinsic or intrinsic 
apoptotic pathways. While the role of the extrinsic 
apoptotic pathway activation in the mucosa of patients 
with CD has been proposed in the literature, studies 
on the intrinsic and common apoptotic pathways in 
patients with CD are sparse[18]. 
It is likely that the development of CD depends 
on the balance between proinflammatory and anti­
inflammatory factors, proapoptotic and antiapoptotic 
signals, as well as prooxidant processes and 
antioxidant capacity of the cell. This imbalance is 
reflected in an impairment of the epithelial barrier 
and increased permeability, leading to activation of 
the immune response (native and adaptive) that 
contributes to cell damage and villous atrophy in 
patients with CD. 
The aim of our study was to determine the in­
volvement of oxidative imbalance in the mechanism of 
mucosal injury of the small intestine and to assess the 
effect of oxidative stress on the course of CD in adult 
patients with non­classic symptoms and extraintestinal 
manifestations. Apart from routine blood parameters, 
the serum concentrations of total vitamin D, uric acid, 
and bilirubin were measured. Moreover, in biopsy 
specimens collected during endoscopy of the proximal 
small intestine from these groups of patients, the 
expression of mRNA for proinflammatory cytokines 
TNF­α and interleukin 1β (IL-1β) as well as an anti-
inflammatory cytokine interleukin 10 (IL-10) was 
determined by reverse transcription–polymerase chain 
reaction (RT­PCR) with specific primers. Oxidative 
stress may influence the expression of HSP­70, 
another marker examined in our study. Since ROS 
were shown to affect the stabilization of HIF­1α RNA 
and activate the intrinsic apoptotic pathway associated 
with overexpression of proapoptotic BAX, we also 
examined the gene expression of HIF­1α, antioxidant 
enzyme SOD, and proapoptotic factor BAX in the 
duodenal tissues of the enrolled patients. 
MATERIALS AND METHODS
All individuals gave informed consent to participate in 
the study. The protocol of the study was approved by 
the Ethical Committee at Jagiellonian University Medical 
College in Cracow, Poland (No KBET/174/B/2013) and 
was run in accordance with the Declaration of Helsinki.
The study included 85 patients of the Outpatient 
Clinic and the Department of Gastroenterology and 
Hepatology of the University Hospital in Cracow 
(Table 1). Patients were divided into the following 
subgroups: (1) 7 patients with newly diagnosed CD 
(age range, 19­62 years; mean age, 34.7 ± 14.9 
years); (2) 22 patients with CD who did not adhere 
to GFD (nontreated CD group; age range, 22­68 
years; mean age, 38.2 ± 10.7 years); (3) 31 patients 
with CD who were on GFD for at least two years and 
who tested negative for celiac antibodies (treated 
CD group; age range, 28­65 years; mean age, 45.7 
± 16.1 years; mean duration, 10 ± 7.7 years); 
and (4) 25 patients with functional disorders of the 
gastrointestinal tract without abnormalities on upper 
gastrointestinal endoscopy and on serological and 
histological examinations (control group; age range 
19­66 years; mean age, 38.5 ± 13.2 years). Groups 1 
and 2 represented patients with active CD.
CD was diagnosed on the basis of clinical sy­
mptoms, positive test results for celiac antibodies 
[antitissue transglutaminase antibodies (TGAs) or 
antiendomysial antibodies (EmAs) or both], and 
the characteristic histological features of duodenal 
biopsies. Celiac patients presented with non­classic 
symptoms or extraintestinal manifestations such 
as iron deficiency, anemia, chronic abdominal pain 
without typical malabsorption syndrome, osteoporosis, 
osteopenia, as well as asymptomatic disease (Table 
2). We excluded patients with diabetes, inflammatory 
bowel disease, current infectious disease, history 
of cancer, chronic hepatobiliary disease, chronic 
renal impairment, and alcohol abuse, or those who 
received therapy with nonsteroidal anti-inflammatory 
drugs, antioxidant supplements, oral contraceptives, 
immunosuppressants, and immunostimulants. All 
patients were nonsmokers.
All patients underwent upper gastrointestinal 
endoscopy, and at least four well­oriented duodenal 
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between the groups, the Student’s t­test was used. 
The results were reported as mean ± SE or mean ± 
SD, and a significance level was defined as a P value 
of less than 0.05. The analysis was performed using 
Statistica 10 software (StatSoft® Inc., United States).
RESULTS
Blood test in controls and celiac patients
The results of biochemical tests are presented in 
Table 4. The mean leukocyte and platelet counts were 
similar between the celiac groups and controls. The 
mean red blood cell count was lower in the active CD 
and treated CD groups as compared with controls (4.49 
± 0.39 vs 4.7 ± 0.37, P < 0.05; 4.45 ± 0.42 vs 4.7 ± 
0.37, P < 0.05, respectively). The mean hemoglobin 
and hematocrit levels were lower in patients with 
active CD than in controls (12.6 ± 1.8 vs 13.4 ± 
1.4, P < 0.05; 37.6 ± 4.4 vs 41.6 ± 9.6, P < 0.05, 
respectively) and treated celiac patients (12.6 ± 1.8 
vs 13.3 ± 1.1, P < 0.05; 37.6 ± 4.4 vs 39.5 ± 3.2, P 
< 0.05, respectively). Only 2 patients (3.3%) with CD 
were anemic (hemoglobin < 11 g/dL), but reduced 
mean corpuscular volume was observed in 11 patients 
(37.9%) with active CD (range, 59.9-81.4 fL), in 3 
patients (3.2%) with treated CD (range, 80.9-81.1 fL), 
and in two controls (8%; range, 80.1-80.4 fL).
The mean serum levels of total protein, alanine 
aminotransferase, alkaline phosphatase, and γ-glu-
tamyltransferase were similar to those observed 
in controls. The mean serum levels of aspartate 
aminotransferase were significantly higher in the active 
CD and treated CD groups compared with controls (28.0 
± 19.3 vs 18.0 ± 8.5, P < 0.05; 23.2 ± 6.5 vs 18.0 ± 8.5, 
P < 0.05, respectively), without significant differences 
between the two CD groups. Hypertransaminasemia 
was reported in 7 patients (24.1%) with active CD, in 
5 patients (16.1%) with treated CD, and in none of the 
control patients. 
Serum uric acid concentrations were elevated only 
in celiac patients, namely, in 3 patients (10.3%) with 
active CD and in 2 patients (6.5%) on GFD. Uric acid 
levels were significantly higher in the celiac groups 
than in controls (P < 0.001), while bilirubin levels were 
significantly lower in patients with CD than in controls (P 
< 0.05).
Reduced vitamin D levels were reported in 26 
patients (89.6%) with active CD, in 21 patients (67.7%) 
with treated CD, and in 14 controls (56%). Moderate 
vitamin D deficiency (10-19 ng/mL) was reported in 
11 patients (37.9%) with active CD and 12 patients 
(< 10 ng/mL) was reported in 3 patients (10.3%) with 
active CD and only in 1 patient (3.2%) with treated 
CD. Moderate to severe vitamin D deficiency was not 
observed in the control group. The mean vitamin D 
specimens were taken for histological examination 
and determination of the IL-1β, TNF­α, IL-10, HSP-70, 
HIF­1α, SOD, and BAX mRNA expression in the 
duodenum. The degree of intestinal mucosal damage 
was evaluated according to the Marsh classification[20]. 
The histological assessment was performed by 
an experienced pathologist in the Department of 
Pathology at Jagiellonian University Medical College.
We determined the serum levels of TGAs and 
EmAs, blood cell count, serum activity of alanine 
aminotransferase, aspartate aminotransferase, al­
kaline phosphatase, γ-glutamyltransferase, and total 
protein, as well as serum levels of antioxidants: uric 
acid, bilirubin, and vitamin D. The TGA concentration 
was assessed using a commercial ELISA kit (Aesku 
Diagnostics GmbH, Germany), and the results were 
expressed as unit (U)/mL of serum. A value higher than 
15 U/mL was considered positive. EmAs were assessed 
with immunofluorescence. A value higher than 1:10 
was considered positive. The other biochemical tests 
were performed in the Department of Diagnostics of 
the University Hospital in Cracow.
Expression of IL-1β, TNF-α, IL-10, HSP-70, HIF-1α, SOD, 
and BAX transcripts in the human intestinal samples 
determined by RT-PCR 
The expression of IL-1β, TNF­α, IL-10, HSP-70, HIF-
1α, SOD, and BAX transcripts in human samples 
was determined by RT­PCR. Each specimen was 
immediately frozen in liquid nitrogen and stored at ­80 
℃ until analysis. Total RNA was then isolated according 
to the method by Chomczynski and Sacchi[21], using 
Trizol Reagent (Invitrogen, Carlsbad, United States) 
following the manufacturer’s protocol. First­strand 
cDNA was synthesized from total cellular RNA (2 
μg) using Reverse Transcription System (Promega, 
Madison, United States). The RT­PCR was carried out 
in an automatic DNA thermal cycler, using 1­µg cDNA 
and Promega PCR reagents. For amplification of IL-1β, 
TNF­α, IL-10, HSP-70, HIF-1α, SOD, and BAX cDNA, 
gene­specific primers were used (SIGMA­Aldrich St. 
Louis, United States) (Table 3). Amplification of control 
human β­actin was performed on the same samples to 
verify the RNA integrity. PCR products were separated 
by electrophoresis in 2% agarose gel containing 0.5 
µg/mL of ethidium bromide and then visualized under 
ultraviolet light. Location of the predicted PCR product 
was confirmed by using the O’Gene Ruler 50 bp DNA 
ladder (Fermentas, Life Sciences, San Francisco, 
United States) as standard marker. 
Statistical analysis 
A statistical analysis was performed by a biomedical 
statistician using a nonparametric Mann­Whitney test. 
For the comparison of normally distributed variables 
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level was significantly lower in patients with active CD 
than in controls or treated celiac patients (P < 0.001 
and P < 0.05, respectively), and was lower in treated 
celiac patients than in controls (P < 0.05).
Serum levels of celiac antibodies and the degree of 
intestinal mucosal damage in the study population
The serum levels of celiac antibodies were negative 
in the control group (Table 5). As expected, the 
significantly higher levels of celiac antibodies were 
observed in patients with active CD. In treated CD 
patients, the levels of antibodies were significantly 
lower compared with untreated CD patients (P < 
0.001). The degree of intestinal mucosal damage 
evaluated according to the Marsh classification as 
shown in Figure 1 and Table 5 was the most severe in 
newly diagnosed CD patients, followed by nontreated 
CD patients, treated CD patients, and controls. The 
differences between the groups were significant. Data 
are presented in Table 5.
Expression of transcripts in human intestinal samples 
determined by reverse-transcriptase polymerase chain 
reaction
Expression of IL-1β, TNF-α, and IL-10: Figure 
2 shows the mRNA expression of proinflammatory 
cytokines IL-1β and TNF­α and the alterations in RT­
PCR mRNA expression of anti­inflammatory cytokine 
A B C
D E
Figure 1  The spectrum of small intestinal damage in the study groups. Hematoxylin and eosin stained biopsy specimens obtained by gastroscopy. A: Normal 
duodenal mucosa: normal villus-to-crypt ratio; intraepithelial lymphocytes (IEL) within the normal range; B: Marsh 1: lymphocytic enteritis (an increase in IEL count); C: 
Marsh 3a: partial villous atrophy with hypertrophic crypts and an increase in IEL count; D: Marsh 3b: subtotal villous atrophy with hypertrophic crypts and an increase 
in IEL count; E: Marsh 3c: total villous atrophy with hypertrophic crypts and an increase in IEL count.
Table 1  Characteristics of the study groups 
Groups of patients Age (yr, mean ± SD)  n  (%)
Total 70.74 ± 14.22 85
   Female 71 (83.5)
   Male 14 (16.5)
Active CD
   Newly diagnosed CD 34.7 ± 14.9  7
   Female 5 (71.4)
   Male   2 (28.6)
   Nontreated CD 38.2 ± 10.7 22
   Female 18 (81.8)
   Male 4 (18.2)
Treated CD 45.7 ± 16.1 31
   Female 28 (90.3)
   Male 3 (9.7)
Control 38.5 ± 13.2 25
   Female 20 (80)
   Male 5 (20)
Active CD: Celiac patients with active disease; Newly diagnosed CD: 
Celiac patients at diagnosis of CD; Nontreated CD: Celiac patients not 
adhering to a gluten-free diet; Treated CD: Celiac patients on a gluten-free 
diet.
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IL-10 in the biopsies of duodenal mucosa. The IL-
1β mRNA expression was not significantly different 
between the study groups, although it was slightly 
higher in active CD as compared with controls and 
patients on GFD. The expression of mRNA for TNF­α 
was significantly increased in all celiac groups when 
compared with controls (P < 0.05). The TNF­α RNA 
expression was similar in both groups of active CD (high 
degree of mucosal damage), but was significantly 
higher than in treated patients (low grade of mucosal 
damage). 
The expression of IL-10 mRNA in the study groups 
was similar to the trend observed for the expression 
of TNF­α mRNA. In intact intestinal mucosa, the signal 
for IL-10 mRNA expression was faint. However, we 
observed a significant increase in the IL-10 mRNA 
expression in the celiac groups when compared with 
controls (P < 0.05). Celiac patients on GFD had a 
lower expression of IL-10 mRNA in the mucosa than 
patients with active disease, and this difference based 
on the semi­quantitative assessment of the ratio of 
IL-10 mRNA expression to β­actin mRNA expression 
was significant (Figure 2). 
Expression of HSP-70 and SOD: As shown in Figure 
3, the signal for the expression of HSP­70 mRNA was 
1.2
0.9
0.6
03
0.0
IL
-1
β 
  
m
R
N
A/
β-
ac
tin
 m
RN
A 
ra
tio
1.5
1.2
0.9
0.6
03
0.0
TN
F-
α
 m
R
N
A/
β-
ac
tin
 m
RN
A 
ra
tio
a
c c
1.5
1.2
0.9
0.6
03
0.0
IL
-1
0 
m
R
N
A/
β-
ac
tin
 m
RN
A 
ra
tio
a
c
c
Control           TCD           NTCD          NDCD
M            1            2             3            4
β-actin
(307 bp)
IL-1β
(141 bp)
TNF-α
(181 bp)
IL-10
(328 bp)
A
B
C
D
Figure 2  The RT-PCR expression of mRNA for β-actin (A), interleukin 1β (B), tumor necrosis factor α (C), and interleukin 10 (D) in duodenal tissue of celiac 
patients and controls. The bands densities [as a ratio of interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α) and IL-10 to the β-actin levels, respectively] are 
expressed as the mean ± SE of 4 determinations in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCD: Newly diagnosed celiac 
group. aP < 0.05 vs control group; cP < 0.05 vs control and treated CD groups.
Table 2  Clinical characteristic of study groups n  (%)
Groups of patients Iron deficiency/anemia Chronic abdominal pain Osteopenia/osteoporosis Menstrual disorders Abnormal liver tests Others
Active CD (n = 29) 11 (37.9) 7 (24.1) 4 (13.8) 1 (3.4) 5 (17.2) 1 (3.4)
Treated CD (n = 31) 15 (48.4) 4 (12.9) 5 (16.1) - 5 (16.1) 2 (6.5)
Active CD: Celiac patients with active disease; Treated CD: Celiac patients on a gluten-free diet.
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markedly increased in the celiac groups compared with 
controls, regardless of compliance with the diet (P < 
0.05). The differences between the celiac groups were 
not significant. 
The ratio of SOD mRNA expression to β­actin 
mRNA expression confirmed that the expression of this 
antioxidant enzyme was significantly elevated in celiac 
patients compared with controls (P < 0.05). The signal 
for SOD mRNA expression in treated CD patients 
was significantly lower than in untreated and newly 
diagnosed ones (Figure 3).
Expression of HIF-1α and BAX: The ratio of HIF­
1α mRNA expression to β­actin mRNA expression 
confirmed that the expression of HIF­1α was 
significantly elevated in the mucosa of patients with 
active CD compared with controls and patients with 
treated CD (P < 0.05). HIF­1α mRNA expression was 
slightly increased in the duodenal mucosa of patients 
with treated CD compared with controls, but the 
difference was not significant (Figure 4). A significant 
increase in the expression of BAX mRNA as determined 
by the ratio of BAX mRNA expression to β-actin mRNA 
expression in the mucosa of patients with active CD 
was observed compared with controls and patients 
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Figure 3  The RT-PCR expression of mRNA for β-actin (A), heat-shock protein 70 (B) and superoxide dismutase (C) in duodenal tissue of celiac patients 
and controls. The band densities [as a ratio of heat-shock protein 70 (HSP-70) and superoxide dismutase (SOD) to the β-actin levels, respectively] are expressed as 
the mean ± SE of 4 determinations in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCD: Newly diagnosed celiac group. aP < 0.05 
vs control group; cP < 0.05 vs control and treated CD groups.
Table 3  Human oligonucleotide primers for detection of mRNA by RT-PCR
Gene Primer sequence t PCR product
IL-1β Forward 5’-ACA TCA GCA CCT CTC AAG -3’, 60 ℃ 141 bp
Reverse 5’-AGT CCA CAT TCA GCA CAG -3’
TNF-α Forward 5’-GCC CAG GCA GTC AGA TCA TCT TC -3’, 58 ℃ 181 bp
Reverse 5-TGA GGT ACA GGC CCT CTG ATG G-3’
IL-10 Forward 5’-AGC TAT CCC AGA GCC CCA GAT CCG ATT TTG G-3’, 60 ℃ 328 bp
Reverse 5’-AAG CTG AGA ACC AAG ACC CAG ACA TCA AGG CG-3’
HSP-70 Forward: 5’-GCC CCA ACA GAT TGT TGT CTT-3’, 59.5 ℃ 111 bp
Reverse: 5’-CCA CCA AGC AGA CGC AGA T-3’
HIF-1α Forward 5’-GGT TCT CAC AGA TGA TGG TG-3’, 60 ℃ 239 bp
Reverse 5’-TTC TTC CTC GGC TAG TTA GG-3’
SOD Forward: 5’-GAA GGT GGG AAG CAT TA-3’, 57 ℃ 300 bp
Reverse: 5’-ACC TTT GCC CAA GTC ATC TG-3’
BAX Forward 5’-CGT CCA ACC CAC CCT GGT CT-3’, 55 ℃ 195 bp
Reverse 5’-TGG CAG CTG ACA TGT TTT CTG AC-3’
β-actin Forward 5’-GGG TAC ATG GTG GTG CCG-3’, 54 ℃ 307 bp
Reverse 5’-AGC GGG AAA TCG TGC GTG-3’
t: Annealing temperature; IL-1β: Interleukin 1β; TNF-α: Tumor necrosis factor alfa; IL-10: Interleukin 10; HSP-70: Heat-shock protein 70; HIF-1α: Hypoxia-
inducible factor 1α; SOD: Superoxide dismutase.
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with treated CD (P < 0.05). We failed to observe any 
significant difference in the expression of BAX mRNA 
in the duodenal mucosa of patients with treated CD 
compared with controls (Figure 4). 
DISCUSSION
Most studies concerning the pathomechanism of CD 
and intestinal changes focused on children with classic 
clinical symptoms of malabsorption syndrome[4,22­24]. 
However, malabsorption alone does not explain the 
pathophysiology and clinical course of numerous 
extraintestinal manifestations as well as non­
classic symptoms that predominate in adult patients 
with CD. Other mechanisms have been proposed 
including gluten toxicity with oxidative imbalance and 
autoimmunity[23,24].
In this study, we have examined less extensively 
studied, factors implicated in CD, such as HSP­70, 
HIF­1α, and the proapoptotic factor BAX. We found 
these 3 factors to be overexpressed in active CD, 
with varying degrees of activity in patients on GFD. 
This overexpression could be triggered by oxidative 
imbalance linked with an increase in ROS generation. 
Each of these factors was shown to influence the 
intestinal barrier integrity. For instance, HSP­70 and 
HIF­1α can contribute to preservation of intestinal 
barrier integrity[5,19], while apoptosis manifested by the 
rise in the BAX expression may lead to disruption of 
the intestinal barrier[25]. The impaired barrier function 
may be involved in several immune­mediated diseases, 
including CD and its extraintestinal manifestations or 
coexisting disorders[26,27].
HSP, a known chaperone, has potential epithelial 
barrier protecting, antiapoptotic, and immunologic 
properties[19], but its role in the pathogenesis of CD 
remains unexplored. Our results presented in this work 
revealed that HSP­70, which is expressed under normal 
conditions, can also play a particularly important role 
in extreme conditions such as gluten cytotoxicity. 
It is noteworthy that the expression of HSP­70 was 
significantly increased in each celiac group in our study 
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Figure 4  The RT-PCR expression of mRNA for β-actin (A), hypoxia-inducible factor 1α (B) and BAX (C) in duodenal tissue of celiac patients and controls. 
The band densities [as a ratio of hypoxia-inducible factor 1α (HIF-1α) and BAX to the β-actin levels, respectively] are expressed as the mean ± SE of 4 determinations 
in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCD: Newly diagnosed celiac group. aP < 0.05 vs control and treated CD groups.
Table 4  Blood test results in the study groups
Controls
(n  = 25)
Active CD
(n  = 29)
Treated CD
(n  = 31)
WBC (103/μL) 5.69 ± 1.55 5.81 ± 1.58 5.36 ± 1.36
RBC (106 cells/μL) 4.7 ± 0.37 4.49 ± 0.39a 4.45 ± 0.42a
Hemoglobin (g/dL) 13.4 ± 1.4 12.6 ± 1.8a,c 13.3 ± 1.1
Hematocrit (%) 41.6 ± 9.6 37.6 ± 4.4a,c 39.5 ± 3.2
PLT (103/μL) 248.52 ± 47.63 267.18 ± 96.8 252.52 ± 64.38
Vitamin D (ng/mL) 29.7 ± 5.1 19.4 ± 9.0b,c 25.2 ± 11.2a
Total protein (g/L) 73.2 ± 6.1 71.2 ± 7.9 71.6 ± 3.3
AST (U/L) 18.0 ± 8.5 28.0 ± 19.3a 23.2 ± 6.5a
ALT (U/L) 22.0 ± 4.3 26.7 ± 20.1 24.2 ± 12.5
AP (U/L) 59.6 ± 19.7 62.2 ± 29.1 59.2 ± 27.3
GGTP (U/L) 24.4 ± 14.6 21.3 ± 13.6 21.3 ± 22.62
bilirubin (μmol/L) 10.5 ± 4.1 8.2 ± 5.0a 8.1 ± 3.3a
Uric acid (μmol/L) 190.8 ± 23.0 260.2 ± 53.7b 261.7 ± 51.8b
Data are given as mean ± SD. aP < 0.05, bP < 0.001 vs controls; cP < 0.05 
vs Treated CD. Active CD: Patients with active CD; Treated CD: Celiac 
patients on a gluten-free diet; WBC: White blood cell count; RBC: Red 
blood cell count; PLT: Platelet count; ALT: Alanine aminotransferase; 
AST: Aspartate aminotransferase; AP: Alkaline phosphatase; GGTP: 
γ-glutamyltransferase.
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regardless of the degree of compliance with the diet. 
A few previous studies evaluated the role of HSP in 
intestinal pathology of patients with CD[19,28­30]. Iltanen 
et al[31] reported enhanced expression of epithelial cell 
mitochondrial HSP­65 in 80% of study children with 
CD and in only 7% of control subjects. Sziksz et al[19] 
reported an increased HSP­72 mRNA expression in 
the duodenal mucosa of children with untreated CD 
as well as children with treated CD compared with 
that in controls. These observations are consistent 
with the results of our study on HSP­70 expression 
in adult patients. Our results indicate that HSP­70 in 
adult CD patients, similarly as HSP­72 in children, was 
overexpressed due to oxidative stress. The increased 
HSP­70 expression may constitute a protective 
mechanism against gliadin­induced cytotoxicity as­
sociated with antiapoptotic effects, thus contributing to 
preservation of intestinal epithelial barrier integrity. 
It should be noted, however, that significant per­
centage of patients with CD on GFD, in our study, 
showed the persistence of duodenal damage despite 
clinical improvement and evident decline in celiac 
antibodies. The main criteria for inclusion in this group 
involved a specialist assessment by gastroenterologist 
and dietitian of patients proper dietary adherence, 
clinical recovery and above all, the negativity of 
serologic markers. Interestingly, a gap has emerged 
between the clinical and mucosal recovery, mainly in 
the adult population, since when re­biopsing treated 
CD patients only half of them had healed mucosa, 
despite the negativity of celiac antibodies[32,33]. Fo­
llowing the GFD, the clinical symptoms and mucosal 
architecture usually improve very quickly in children[34], 
while in a mixed population including adults, the 
recovery of duodenal mucosa assessed by histology 
requires longer time to heal[35]. These previous 
observations seem consistent with the results of our 
present study because the morphological alterations 
persisted in some of our CD patients despite the clear 
disappearance of specific antibodies. The increased 
expression of HSP­70 in treated and untreated celiac 
patients indicates that oxidative stress in patients 
with CD may still persist despite GFD and serological 
and clinical remission, and may be responsible for 
histopathological alterations observed in our study. 
Finally, the enhanced expression of HSP­70 suggest 
incomplete elimination of all sources of gluten in 
modern diet. Perhaps the expression of HSP­70 could 
be considered as a more sensitive marker than celiac 
antibodies in the detection of the trace amounts of 
gluten in diet. Thus, HSP­70 could be considered a 
potential novel biomarker of this disease. 
It is known that ROS and HIF­1 signaling are 
involved in numerous diseases including cancer, in­
flammatory diseases, and ischemic disorders[12]. 
Furthermore, the increase of ROS levels is one of the 
main factors stabilizing HIF­1α. It has been shown 
that exogenous ROS, in the form of H2O2, can enhance 
the synthesis of inflammatory mediators such as 
TNF­α and IL-1β[36], which in turn can influence the 
protein transcription and activity of HIF­1α under 
normoxia[37]. We provided evidence for the increased 
mucosal HIF­1α expression in untreated adult patients 
with active CD compared with controls and treated 
CD patients, while we did not observe any significant 
difference between treated celiac patients and 
controls. This observation is consistent with that of 
Vannay et al[11], who suggested the role of HIF­1α in 
the pathomechanism of CD. In addition, involvement 
of HIF­1 in inflammatory bowel disease has been 
reported[10]. The increased expression of HIF­1α in 
our study can be explained by the initial intestinal 
damage or the direct effect of gluten in diet. These 
data suggest that increased HIF­1α expression may 
Piątek-Guziewicz A et al . Oxidative imbalance in CD
Control (n  = 25) Treated CD (n  = 31) Nontreated CD (n  = 22) Newly diagnosed CD (n  = 7)
Antibody titer 
   0 25 30 (96.7) 0 0
   1 0 1 (3.3) 9 (40.9) 1 (14.3)
   2 0 0 3 (13.6) 2 (28.6)
   3 0 0 10 (45.5) 4 (57.1)
Antibody titer 0 0.03 ± 0.2 2.0 ± 0.9b,d 2.4 ± 0.8b,d
Degree of intestinal mucosal damage1
   Normal mucosa   0 24 (96) 13 (41.3) 2 (9) 1 (14.3)
   Marsh 1                 1 1 (4) 5 (16.1) 7 (31.8) 0
   Marsh 2                 2 0 0 0 0
   Marsh 3a               3 0 5 (16.1) 6 (27.3) 1 (14.3)
   Marsh 3b               4 0 7 (22.6) 5 (22.7) 3 (42.9)
   Marsh 3c               5 0 1 (3.2) 2 (9) 2 (28.6)
Intestinal mucosal damage1 0.04 ± 0.2 1.7 ± 1.8b 2.5 ± 1.6b,c 3.7 ± 1.4b,c
1Intestinal mucosal damage was classified according to Marsh parameters, and each stage was given a score from 0 (normal mucosa) to 5 (total villous 
atrophy). bP < 0.001 vs controls; cP < 0.05, dP < 0.001 vs treated CD. Data are frequency counts (percentage of total) or the mean ± SD. Treated CD: Celiac 
patients on a gluten-free diet; Nontreated CD: Celiac patients not adhering to a gluten-free diet; Newly diagnosed CD: Celiac patients at diagnosis of CD; 
antibody titer 0: Negative; 1: Low [TGA <3x the upper limit of normal (ULN); EmA (+)]; 2: High [3xULN<TGA<10x ULN ; EmA (++)], 3: Very high [TGA>10x 
ULN; EmA (+++)]. 
Table 5  Clinical characteristics of the study groups: serum levels of celiac antibodies and the degree of intestinal mucosal damage n  
(%)
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be a consequence rather than a primary cause of CD. 
Moreover, the decreased mucosal expression of HIF­1α 
in treated CD may confirm the efficacy of GFD. 
In general, data on the status of apoptosis in 
patients with CD are conflicting, but increased apoptotic 
cell death of intestinal epithelial cells was reported 
in untreated CD, as detected by DNA fragmentation 
assay using terminal uridine deoxynucleotidyl nick end 
labelling in small intestinal biopsies[38]. In that study, 
apoptosis was well correlated with proliferation and 
returned to normal in patients treated with GFD[38]. It is 
likely that increased apoptosis may be responsible for 
villous atrophy in CD. Therefore, our study included RT­
PCR analysis of the proapoptotic member of the Bcl­2 
family, that is, BAX, which in normal mucosa showed 
constitutive expression. This remains in keeping 
with the observation that the mucosa of healthy 
individuals undergoes a high rate of constitutive epi­
thelial proliferation[17]. In our study, the expression 
of BAX showed a similar trend to that observed for 
the expression of HIF­1α. We revealed a significantly 
elevated BAX mRNA expression in the duodenal 
mucosa of patients with active CD compared with 
controls and patients with treated CD. Interestingly, 
the expression of BAX mRNA in the duodenal mucosa 
was not significantly different between treated CD 
patients and controls. Our results suggest that the 
increased expression of BAX results from the severity 
of intestinal inflammation and gluten-induced oxidative 
stress and leads to duodenal villous atrophy. Moreover, 
the decreased mucosal expression of BAX in treated 
CD patients may indicate the relief of inflammation 
and thus the efficacy of treatment. In contrast to our 
study, van der Woude et al[38] failed to demonstrate 
any changes in the expression of BAX, Bcl­2, and Bcl­
xl between their study groups, which were similar to 
those in our study. However, Cherñavsky et al[39] found 
that only Bak mRNA was significantly overexpressed 
in the mucosa of CD patients, whereas BAX and Bcl­2 
transcription levels were unchanged with respect to 
control mucosa.
Oxidative imbalance seems to be involved in the 
molecular mechanisms of CD. In normal conditions, the 
harmful effects of ROS are opposed by the antioxidant 
defense system consisting of antioxidant enzymes 
(glutathione peroxidase, glutathione reductase, SOD, 
and catalase), non­enzymatic antioxidants (such as 
glutathione, albumin, bilirubin, ceruloplasmin, and uric 
acid) as well as nutritional antioxidants (carotenoids 
and vitamins A, C, and E)[40]. The reduced antioxidant 
defense may make the inflamed mucosa more 
sensitive to oxidative tissue damage and may disrupt 
its recovery and integrity. 
Using thiobarbituric acid reactive substances as a 
marker of oxidative stress, Odetti et al[41] showed that 
redox equilibrium is impaired in patients with CD. They 
also observed decreased serum α­tocopherol levels 
in patients with silent CD in comparison with controls. 
Earlier studies also showed that the activity of SOD is 
markedly increased in pediatric patients with CD, while 
the activity of glutathione peroxidase is significantly 
decreased[24]. 
SOD, which reduces the most abundant free radical 
•O2, is considered as the major intracellular antioxidant 
enzyme[40]. In agreement with previous data, our 
results demonstrated overexpression of SOD mRNA in 
the mucosa of celiac patients compared with controls. 
We observed an increased expression of SOD mRNA 
in active disease, and this increase was attenuated 
in the treated celiac group. These results suggest 
that the increased expression of SOD, reflecting the 
severity of oxidative stress in duodenal mucosa, could 
be a consequence of either intestinal impairment or of 
oxidative imbalance. Our observations may indicate 
that some markers of oxidative stress persist even in 
treated CD patients, but GFD partially counteracts the 
impairment of intestinal mucosa observed in active CD 
patients. 
There is increasing experimental and clinical 
evidence showing that uric acid acts as an important 
antioxidant in vivo[42]. Interestingly, an increase in 
serum uric acid concentrations occurs as a physiological 
response to enhanced oxidative stress[43]. Despite 
being a major antioxidant in the human plasma, uric 
acid correlates with and may predict the development 
of conditions associated with oxidative stress such as 
obesity, hypertension, and cardiovascular disease[44]. 
Our results indicate that higher serum levels of uric 
acid in patients with CD compared with controls may 
be a consequence of oxidative stress and that uric 
acid may function as an antioxidant. Additional well­
designed clinical studies are needed to clarify the 
potential use of uric acid (or uric acid precursors) in CD 
and to examine its role as a marker of oxidative stress 
and a potential therapeutic antioxidant. 
In contrast to transaminases, the levels of bilirubin 
in patients with CD were significantly lower than in the 
control group. Bilirubin is an antioxidant that blocks 
vascular cell adhesion molecule 1 signals through ROS 
in vitro[45]. An Australian study[46] reported that bilirubin 
levels were significantly lower in severe asthma, 
suggesting altered regulation of inflammation in 
asthmatics by antioxidant vitamins and bilirubin. This 
observation is consistent with our results, indicating 
the relationship between the altered concentration of 
bilirubin and oxidative imbalance. However, the role of 
bilirubin in oxidative imbalance in CD requires further 
research. 
A significant number of CD patients with intestinal 
malabsorption syndrome present vitamin D deficiency 
or insufficiency. In our study, vitamin D deficiency 
was noted in celiac patients despite the absence of 
clinical syndrome of malabsorption, possibly because 
inflammation may also lead to vitamin D deficiency. 
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It is likely that inflammatory cytokines, such as 
TNF­α, cause CYP27B1­mediated conversion of 
25(OH)D to 1,25(OH)2D in the intestines, thereby 
reducing serum 25(OH) D levels[47]. In turn, the 
active form of 1,25(OH)2D inhibits the proliferation 
and secretion of inflammatory cytokines by type 1 
helper T cells, thereby reducing inflammation[48]. This 
inverse relationship between the activity of CD and 
serum vitamin D levels was observed in our study. 
A similar observation concerns the degree of TNF­α 
expression and the degree of vitamin D deficiency, 
which is consistent with the results obtained in previous 
studies in healthy individuals[49,50]. The antioxidant 
property of vitamin D is rather less well recognized. 
Cholecalciferol (vitamin D3) is likely to act as a 
membrane antioxidant by stabilizing the membrane 
against lipid peroxidation[51]. The antioxidant activity of 
vitamin D may involve an interaction with SOD[52]. We 
showed that a decrease in serum vitamin D levels in 
patients with CD was accompanied by an increase in 
the intestinal mucosal expression of TNF­α, suggesting 
that overexpressed TNF­α may lead to a reduction 
in the serum level of vitamin D. In turn, an increase 
in SOD expression may result from enhancement of 
TNF­α expression and a prominent fall in serum vitamin 
D levels which activate the antioxidative defense. This 
indicates that early diagnosis of vitamin D deficiency 
is particularly important in patients with CD, especially 
in those who do not comply with GFD. Therefore, the 
supplementation of vitamin D is recommended not only 
for bone metabolism but also for effective treatment of 
intestinal damage in patients with CD by reducing the 
oxidative stress. 
A drawback of this study is a relatively small number 
of patients in each celiac subgroups, and definitely a 
further research with higher number of enrolled subjects 
is required to support our observations. It is noteworthy 
that the morphology of duodenal mucosa failed to show 
a full recovery despite the proper adherence to GFD, 
clinical improvement and the status of seroconversion, 
i.e. the decline in the value of antibodies in this group 
of patients to a negative result. Hence, further research 
with only subjects presenting full mucosal healing would 
add more to our understanding of pathomechanism of 
CD and intestinal recovery associated with GFD. 
In conclusion, by its association with intestinal 
damage, the course of the disease, and perhaps 
extraintestinal disorders, oxidative imbalance appears 
to be one of the major factors implicated in the 
pathogenesis of CD. Our results support the hypothesis 
that HSP­70 may be a potential novel biomarker in 
CD. The increased intestinal expression of HSP­70 in 
patients with active CD and in treated celiac patients 
indicates that oxidative stress persists despite the 
exclusion of gluten from diet which deepens our 
knowledge on multifaceted mechanisms of this disease. 
This persistent oxidative imbalance may be responsible 
for sustained intestinal damage in CD despite GFD. In 
fact, the significant overexpression of HSP-70 despite 
dietary compliance may suggest refractory nature of 
CD. Furthermore, particularly noteworthy are non­
enzymatic antioxidants, such as uric acid and bilirubin, 
whose concentration may be easily assessed in 
patients with CD. 
Considering that several nutrients exert antioxidant 
effects and influence gene expression, they represent 
a useful approach for nutritional intervention in CD 
subjects, as confirmed by recent studies in vitro. 
These studies have revealed phytonutrients and 
docosahexaenoic acid efficacy in protection against the 
cytotoxic effect of gliadin[53­55]. 
To become aware of the usefulness of nutritional 
genomics as a tool for targeted medical nutrition 
therapy, further basic research, epidemiological 
studies and controlled intervention trials are needed to 
investigate whether some nutrients such as antioxidant 
vitamins modulate in vivo predisposition of chronic 
inflammatory conditions and thus, have a role in the 
therapy of celiac disease, in addition to the rigorous 
GFD.
ARTICLE HIGHLIGHTS
Research background
Celiac disease (CD) is a common condition. The only effective treatment 
available is a strict life-long gluten-free diet (GFD). Untreated CD can have 
serious complications, such as osteoporosis or malignancy. Some patients do 
not report symptomatic improvement after starting treatment, and some will 
still have persisting symptoms after 6 to 12 mo. The literature suggests that 
complete normalization of duodenal lesions is exceptionally rare in adult celiac 
patients despite adherence to GFD. 
Research motivation
There is an increasing body of evidence suggesting a relationship between 
oxidative stress and CD. It has been proposed that oxidative stress is one of the 
mechanisms responsible for gliadin toxicity and persistent oxidative imbalance 
may be responsible for sustained intestinal damage in CD despite GFD.
Research objectives 
The assessment of the severity of oxidative stress, including the evaluation of 
antioxidant capacity, in patients with CD may have therapeutic implications. 
The indication of a proper new biomarkers useful in assessing the individual 
susceptibility to oxidative stress, which may help elucidate the pathogenesis of 
the disease and implement an appropriate treatment.
Research methods
To determine the involvement of oxidative stress in the mechanism of mucosal 
injury of the small intestine and to assess the effect of oxidative stress on the 
course of CD in adult patients with non-classic symptoms and extraintestinal 
manifestations, we determined the expression of IL-1β, TNF-α, IL-10, HSP-70, 
HIF-1α, SOD and BAX transcripts in human duodenal samples by reverse 
transcriptase–polymerase chain reaction. 
Research results
The authors found HSP-70, HIF-1α, and BAX to be overexpressed in active CD, 
with varying degrees of activity in patients on GFD. This overexpression could 
be triggered by oxidative imbalance linked with an increase in ROS generation. 
We observed an increased expression of SOD mRNA in active disease, and 
this increase was attenuated in the treated celiac group. These results suggest 
that the increased expression of SOD, reflecting the severity of oxidative stress 
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in duodenal mucosa, could be a consequence of either intestinal impairment or 
of oxidative imbalance.
Our results indicate that oxidative stress persists even in CD patients 
treated with GFD. Moreover, the results suggest that HSP-70 and HIF-1α 
may be potential novel biomarkers of this disease. The overexpression of 
HSP-70 despite dietary compliance may suggest refractory nature of CD. The 
increased levels of uric acid in patients with CD compared with controls resulting 
from oxidative stress indicates that uric acid may function as an antioxidant 
compound.
Further research with a greater number of participants is needed to confirm 
our results. Further clinical studies are needed to clarify the potential therapeutic 
role of uric acid as an antioxidant in CD.
Research conclusions
This study deepens the current knowledge on the role of oxidation products on 
the CD. By its association with intestinal damage, the course of the disease, 
and perhaps extraintestinal disorders, oxidative imbalance appears to be one 
of the major factors implicated in the pathogenesis of CD. Our observations 
may indicate that some markers of oxidative stress persist even in treated CD 
patients, but GFD partially counteracts the impairment of intestinal mucosa 
observed in active CD patients. Persistent oxidative imbalance may be 
responsible for sustained intestinal damage in adult celiac patients despite 
GFD. Perhaps the expression of HSP-70 could be considered as a more 
sensitive marker than celiac antibodies in the detection of the trace amounts of 
gluten in diet. Thus, HSP-70 could be considered a potential novel biomarker 
of this disease. Additional well-designed clinical studies are needed to clarify 
the potential use of uric acid (or uric acid precursors) in the diagnosis and 
prognosis of CD and to examine its role as a marker of oxidative stress and a 
potential therapeutic utility as an antioxidant. Considering that oxidative stress 
is involved in the molecular mechanisms of CD, additional measures aimed at 
reducing oxidative imbalance, such as administration of antioxidants, deserve 
attention as potential supplementary therapy in the treatment of CD, in addition 
to the rigorous GFD.
Research perspectives
Studies comparing the different assays for antioxidant capacity measurement 
in patients with CD are needed to select the method of choice that would best 
reflect susceptibility to oxidative stress in these patients. These assays might be 
particularly useful in clinical practice as a tool for therapy monitoring in patients 
with CD. It should be hypothesized that oral antioxidant supplementation may 
reduce the toxic effects of peptides contained in gluten on enterocytes and help 
alleviate histological lesions, thus exerting beneficial effects on the course of the 
disease. To become aware of the usefulness of nutritional genomics as a tool 
for targeted medical nutrition therapy, further basic research, epidemiological 
studies and controlled intervention trials are needed to investigate whether 
some nutrients such as antioxidant vitamins modulate in vivo predisposition of 
chronic inflammatory conditions and thus have a role in the therapy of celiac 
disease, in addition to the rigorous GFD.
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